Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Neumora Therapeutics Q3 2026 Results: Net Loss of $34.4M, Loss Narrows

Neumora Therapeutics reported a net loss of $34.4 million for the third quarter of 2026, an improvement from the $56.8 million loss in the prior year period. The company's cash and cash equivalents decreased significantly to $85.7 million as of September 30, 2026, compared to $182.5 million at the end of 2025, while total stockholders' equity fell to $18.6 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-34.4-56.8
Net income-34.4-56.8
EPS (diluted, $ a share)$-0.18$-0.35

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: NMRA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Neumora Therapeutics, Inc.: key numbers

Share price
$0.3345Close, Nov 17
Market cap
$63.1M
Shares outstanding
188.69MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Neumora Therapeutics, Inc.

All →
8:04 AM ET 8-K
Business Update

Neumora Therapeutics Business Update

Neumora Therapeutics reported third quarter 2026 financial results and provided a pipeline update, including the submission of an IND application for NMRA-215 in obesity. The company reported a cash position of $85.7 million and noted that it will require substantial additional funding to continue operations and complete product development.

4:05 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Neumora Therapeutics Nasdaq/NYSE Compliance Notice

Neumora Therapeutics received a deficiency notice from Nasdaq for failing to maintain the $1.00 minimum bid price requirement for its common stock. The company has 180 calendar days, until April 26, 2027, to regain compliance by having its stock close at $1.00 or higher for at least ten consecutive business days.

Counterparty
The Nasdaq Stock Market LLC
Term
180 days

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.